ArticleBMC endocrine disorders2026
Association of metabolic syndrome and its components with systemic lupus erythematosus.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic lupus erythematosus (SLE) patients might manifest an increased prevalence of Metabolic syndrome (MetS) components like insulin resistance, obesity, and dyslipidemia. Here we aimed to assess the interconnection between MetS components and SLE and attempted to divulge the potential contribution of MetS on SLE development.
methodsWe enrolled 200 cases with SLE whose diagnosis was accomplished by American College of Rheumatology (ACR) criteria. MetS diagnosed was accomplished through the International Diabetes Federation (IDF) criteria.
resultsThe frequency of MetS among the SLE population was 28.5%. SLEDAI was not significantly different between SLE cases with and without MetS (P = 0.3519). CRP level was significantly higher in the SLE cases with MetS compared to those without MetS (P = 0.0412). BMI, FBS, WC (both in males and females), total cholesterol, TG, and LDL were significantly higher in SLE subjects with MetS compared to those without MetS. However, in both males and females, HDL level was significantly lower in SLE subjects with MetS compared to those without MetS. Obesity, CVD, T2D, dyslipidemia, and hypertension were more prevalent in MetS cases among the SLE population.
conclusionsAn increased prevalence of MetS in the SLE population was observed, while these patients did not have worsen disease severity. All conventional components of MetS were associated with MetS development in the SLE population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.